Guest guest Posted December 26, 2010 Report Posted December 26, 2010 Some trials don't want a full cross section of CLL patients, but select out younger, fitter patients with no comorbidities. The CLL8 trial is a case in point. In other comparative drug trials, the 'new' drug is often compared to an old drug. In CLL chlorambucil is often this comparator and it has been in the past administered at less than optimum dosages. This skews the trial in the favour of the new drug being successful. I think that if public money is being pumped into these trials (how many are funded), that the investigators should be required to publish the results, good or bad. Currently, if the trial is terminated and the results never published. Also the data from the trials should be placed in the public domain, for others to use should they wish to. The FCR + Lumiliximab (LUCID) trials was terminated last August and perhaps I have missed it, but I never saw much published. The only paper to come to light is by Dr. J. Byrd with a commentary by T. Robak. But in North America the writing is on the wall... if we don't start using clinical trials they are going off shore to countries were there is less expense and a greater demand. People have commented to me that it will never happen in CLL because of differences in the ethnicity, but I remind them that Hungary, Poland, Belarus, Lithuania, Russia, and the Ukraine is full of CLL patients with Ashkenazi Jewish heritage, one of the major ethnic groups inflicted with CLL. http://www.nature.com/leu/journal/v12/n10/abs/2401140a.html ~chris Quote
Guest guest Posted December 26, 2010 Report Posted December 26, 2010 Regarding participation rates here versus abroad, here in the States, if your treating doc is not investigator or a member of a cooperative group, a referral to a trial is rare. " Many cancer patients live far from treatment centers, and many health insurers do not pay for experimental therapies—barriers that don't exist in the United Kingdom. Moreover, all U.K. oncologists belong to the cancer network. By contrast, collaborative groups in the United States require membership, and not all oncologists are members. " http://jnci.oxfordjournals.org/content/99/6/420.full Off label use of drugs approved for another indication is also a barrier to trial participation cited in this article. Karl > > Some trials don't want a full cross section of CLL patients, but select out > younger, fitter patients with no comorbidities. The CLL8 trial is a case in point. > > In other comparative drug trials, the 'new' drug is often compared to an old > drug. > > In CLL chlorambucil is often this comparator and it has been in the past > administered at less than optimum dosages. This skews the trial in the favour of > the new drug being successful. > > I think that if public money is being pumped into these trials (how many are > funded), that the investigators should be required to publish the results, good > or bad. Currently, if the trial is terminated and the results never published. > Also the data from the trials should be placed in the public domain, for others > to use should they wish to. > > The FCR + Lumiliximab (LUCID) trials was terminated last August and perhaps I > have missed it, but I never saw much published. The only paper to come to light > is by Dr. J. Byrd with a commentary by T. Robak. > > But in North America the writing is on the wall... if we don't start using > clinical trials they are going off shore to countries were there is less expense > and a greater demand. > > People have commented to me that it will never happen in CLL because of > differences in the ethnicity, but I remind them that Hungary, Poland, Belarus, > Lithuania, Russia, and the Ukraine is full of CLL patients with Ashkenazi Jewish > heritage, one of the major ethnic groups inflicted with CLL. > > http://www.nature.com/leu/journal/v12/n10/abs/2401140a.html > > ~chris > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.